L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis

• Status: Recruiting
• Trial end date: 2026-03-05
• Target enrollment: 0
• Participant gender: All

Summary

This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid arthritis via targeting Jak/STAT pathway and TGF-β1

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University

Criteria

Inclusion Criteria:

• Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria (9) i.e., 28 joints disease activity score (DAS-28) >2.6.

• Patients receive the conventional DMARDs

• Both sexes.

• Age range between 18 and 70 years old.

Exclusion Criteria:

• Patients with heart disease (congestive heart failure, arrhythmia, hypertension, ischemic heart diseases), diabetes, active infection, other illness except rheumatoid arthritis.

• Patients with renal and hepatic dysfunction.

• Patients receiving biological DMARDs.

• Patients receiving oral prednisolone greater than 15 mg/day.

• Patients with hypersensitivity to study medications.

• Patients using antioxidants.

• Pregnant and lactating females.